All In MedTech

Device Trial Radar · NCT03230747

SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation

Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Sep 14, 2017

Primary completion

Jun 16, 2021

Study completion Aug 20, 2026

Sponsor

Lead sponsor
Edwards LifesciencesPublic (EW)
Sponsor type
Industry
First posted
Jul 26, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and functionality of the SAPIEN M3 System in patients with symptomatic, severe MR and will provide guidance for future clinical study designs utilizing the SAPIEN M3 System.

Conditions

  • Mitral Regurgitation
  • Mitral Disease

Interventions

  • Edwards SAPIEN M3 SystemDevice

    SAPIEN M3 System includes the SAPIEN M3 valve and the SAPIEN M3 dock

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Technical SuccessTime frame: At the end of the procedure

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center Heart Institute

    Los Angeles, California

  • California Pacific Medical Center

    San Francisco, California

  • Emory University

    Atlanta, Georgia

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.